Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 146

1.

Osteoprotegrin knockout mice demonstrate abnormal remodeling of the otic capsule and progressive hearing loss.

Zehnder AF, Kristiansen AG, Adams JC, Kujawa SG, Merchant SN, McKenna MJ.

Laryngoscope. 2006 Feb;116(2):201-6.

2.

Osteoprotegerin in the inner ear may inhibit bone remodeling in the otic capsule.

Zehnder AF, Kristiansen AG, Adams JC, Merchant SN, McKenna MJ.

Laryngoscope. 2005 Jan;115(1):172-7.

PMID:
15630389
3.

Resorption of auditory ossicles and hearing loss in mice lacking osteoprotegerin.

Kanzaki S, Ito M, Takada Y, Ogawa K, Matsuo K.

Bone. 2006 Aug;39(2):414-9. Epub 2006 Mar 24.

PMID:
16564235
4.

Bisphosphonate therapy ameliorates hearing loss in mice lacking osteoprotegerin.

Kanzaki S, Takada Y, Ogawa K, Matsuo K.

J Bone Miner Res. 2009 Jan;24(1):43-9. doi: 10.1359/jbmr.080812.

5.

Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function.

Udagawa N, Takahashi N, Yasuda H, Mizuno A, Itoh K, Ueno Y, Shinki T, Gillespie MT, Martin TJ, Higashio K, Suda T.

Endocrinology. 2000 Sep;141(9):3478-84.

PMID:
10965921
6.

Enhancement of crude bone morphogenetic protein-induced new bone formation and normalization of endochondral ossification by bisphosphonate treatment in osteoprotegerin-deficient mice.

Tabuchi M, Miyazawa K, Kimura M, Maeda H, Kawai T, Kameyama Y, Goto S.

Calcif Tissue Int. 2005 Oct;77(4):239-49. Epub 2005 Sep 28.

PMID:
16193235
7.
8.

Stimulation of osteoprotegerin production is responsible for osteosclerosis in mice overexpressing TPO.

Chagraoui H, Tulliez M, Smayra T, Komura E, Giraudier S, Yun T, Lassau N, Vainchenker W, Wendling F.

Blood. 2003 Apr 15;101(8):2983-9. Epub 2002 Dec 27.

9.

Differences in gene expression between the otic capsule and other bones.

Stankovic KM, Adachi O, Tsuji K, Kristiansen AG, Adams JC, Rosen V, McKenna MJ.

Hear Res. 2010 Jun 14;265(1-2):83-9. doi: 10.1016/j.heares.2010.02.006. Epub 2010 Feb 8.

10.

Studies of otic capsule morphology and gene expression in the Mov13 mouse--an animal model of type I osteogenesis imperfecta.

Stankovic KM, Kristiansen AG, Bizaki A, Lister M, Adams JC, McKenna MJ.

Audiol Neurootol. 2007;12(5):334-43. Epub 2007 Jun 26.

PMID:
17595534
11.

Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption.

Kostenuik PJ, Shalhoub V.

Curr Pharm Des. 2001 May;7(8):613-35. Review.

PMID:
11375772
13.

Differential gene expression in the otic capsule and the middle ear--an annotation of bone-related signaling genes.

Nielsen MC, Martin-Bertelsen T, Friis M, Winther O, Friis-Hansen L, Rye-Jørgensen N, Bloch S, Sørensen MS.

Otol Neurotol. 2015 Apr;36(4):727-32. doi: 10.1097/MAO.0000000000000664.

PMID:
25406873
14.

The effect of sex hormones on bone metabolism of the otic capsule--an overview.

Horner KC.

Hear Res. 2009 Jun;252(1-2):56-60. doi: 10.1016/j.heares.2008.12.004. Epub 2008 Dec 24. Review.

PMID:
19121641
15.

Effects of osteoprotegerin administration on osteoclast differentiation and trabecular bone structure in osteoprotegerin-deficient mice.

Yamazaki H, Sasaki T.

J Electron Microsc (Tokyo). 2005 Oct;54(5):467-77. Epub 2005 Dec 9.

PMID:
16339792
16.

Gene therapy with human osteoprotegerin decreases callus remodeling with limited effects on biomechanical properties.

Ulrich-Vinther M, Schwarz EM, Pedersen FS, Søballe K, Andreassen TT.

Bone. 2005 Dec;37(6):751-8. Epub 2005 Sep 19.

PMID:
16169783
17.

Effects of a dexamethasone-releasing implant on cochleae: A functional, morphological and pharmacokinetic study.

Liu Y, Jolly C, Braun S, Janssen T, Scherer E, Steinhoff J, Ebenhoch H, Lohner A, Stark T, Kiefer J.

Hear Res. 2015 Sep;327:89-101. doi: 10.1016/j.heares.2015.04.019. Epub 2015 May 15.

PMID:
25987502
18.

[Bone remodeling and mineral homeostasis].

Nakamura M, Udagawa N, Nakamura H.

Clin Calcium. 2006 Jan;16(1):46-53. Review. Japanese.

PMID:
16397350
19.

Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro.

Yasuda H, Shima N, Nakagawa N, Mochizuki SI, Yano K, Fujise N, Sato Y, Goto M, Yamaguchi K, Kuriyama M, Kanno T, Murakami A, Tsuda E, Morinaga T, Higashio K.

Endocrinology. 1998 Mar;139(3):1329-37.

PMID:
9492069
20.

RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function.

Schoppet M, Preissner KT, Hofbauer LC.

Arterioscler Thromb Vasc Biol. 2002 Apr 1;22(4):549-53. Review.

Supplemental Content

Support Center